Mutations affecting RNA splicing factors are the most common genetic alterations in myelodysplastic syndrome (MDS) patients and occur in a mutually exclusive manner. The basis for the mutual exclusivity of these mutations and how they contribute to MDS is not well understood. Here we report that although different spliceosome gene mutations impart distinct effects on splicing, they are negatively selected for when coexpressed due to aberrant splicing and downregulation of regulators of hematopoietic stem cell survival and quiescence. In addition to this synthetic lethal interaction, mutations in the splicing factors SF3B1 and SRSF2 share convergent effects on aberrant splicing of mRNAs that promote nuclear factor kB signaling. These data identify shared consequences of splicing-factor mutations and the basis for their mutual exclusivity.
Correspondence rbradley@fredhutch.org (R.K.B.), abdelwao@mskcc.org (O.A.-W.) In Brief Lee et al. report that SF3B1 and SRSF2 mutations elicit distinct effects on splicing and are synthetically lethal due to the cumulative impact on hematopoietic stem cell survival and quiescence. These mutations share convergent effects on promoting NF-kB signaling to drive myelodysplastic syndrome.
INTRODUCTION
Recurrent mutations in genes encoding spliceosome components have been identified across multiple cancer types. Spliceosomal gene mutations most commonly occur in myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML) (Papaemmanuil et al., 2011; Yoshida et al., 2011) , chronic lymphocytic leukemia (CLL) (Wang et al., 2011) , and uveal melanoma (Harbour et al., 2013; Martin et al., 2013) . SF3B1, U2AF1, and SRSF2 are the
Significance
Mutual exclusivity of different mutations that affect a single pathway in cancer is commonly thought to indicate convergent effects of these mutations. RNA splicing-factor mutations constitute the most common class of alterations in patients with myelodysplastic syndromes and are also frequent in several additional cancer types, and occur as heterozygous mutations at restricted residues in a mutually exclusive manner. The mutual exclusivity of spliceosomal mutations suggests synthetic lethal and/or convergent biological effects of these mutations; however, there is currently no functional evidence supporting either of these possibilities. Here we report that individual spliceosomal mutations have non-overlapping effects on splicing and are mutually exclusive due to both synthetic lethal interactions and convergent effects on hyperactivation of innate immune signaling. most commonly mutated genes. Mutations in each of these occur as heterozygous point mutations at specific residues, suggesting gain-of-function alterations. In addition, mutations in spliceosome genes are mutually exclusive with one another, presumably due to redundant effects and/or a limit on cellular tolerance of disrupted spliceosome function.
Despite insights into the effects of each mutation on premRNA splicing, the basis for their mutual exclusivity, and functionally convergent effects they may have are unknown. For example, recent work identified that mutations affecting the core splicing factor SF3B1 are associated with cryptic 3 0 splice site selection and altered branchpoint recognition (Darman et al., 2015; DeBoever et al., 2015) . In contrast, mutations affecting SRSF2, an auxiliary splicing factor that binds exonic splicing enhancers to promote splicing, alter its RNA binding preference in a sequence-specific manner and thereby alter the efficiency of exon inclusion (Kim et al., 2015; Zhang et al., 2015) . Finally, mutations affecting U2AF1 either promote or repress 3 0 splice site based on sequences flanking the AG dinucleotide (Ilagan et al., 2014) . Given that the effects of SF3B1, U2AF1, and SRSF2 mutations on splicing mechanisms are distinct, it is unclear why these mutations are mutually exclusive. Moreover, evaluation of the effects of these mutations on splicing and gene expression in an isogenic manner has not been performed. Here we directly assessed the functional basis for the mutual exclusivity of spliceosome gene mutations using models expressing single-or double-mutant splicing factors simultaneously. These data provide a functional explanation for the genetic configuration of spliceosome gene mutations and identify a convergent effect of these mutations on a pathway of established relevance to MDS pathogenesis.
RESULTS

Simultaneous Expression of Srsf2 and Sf3b1 Mutations Is Incompatible with Hematopoiesis
Evaluation of sequencing data from >4,000 patients with myeloid neoplasms revealed that while $48% (1,935/4,032) have a mutation in an RNA splicing factor, only $2% of patients (86/4,032) have >1 splicing-factor mutation ( Figure 1A and Table S1 ). To understand the basis of this mutual exclusivity, we generated mice for inducible heterozygous expression of two of the most common splicing-factor mutations in MDS (SF3B1 K700E and SRSF2
P95H
) simultaneously ( Figure 1B ). We performed noncompetitive bone marrow transplantation (BMT), whereby each mutation was induced following stable engraftment in recipient mice ( Figure 1B ). Bone marrow (BM) cells co-expressing Srsf2 P95H and Sf3b1 K700E mutations were severely defective in multi-lineage reconstitution compared with other groups ( Figures 1C, 1D , and S1A-S1D). Chimerism analysis and evaluation for recombination prior to polyinosinic-polycytidylic acid (pIpC) administration confirmed minimal spontaneous excision prior to BMT (Figures S1E and S1F) . In competitive BMT ( Figure 1E ), BM cells co-expressing Sf3b1 K700E and Srsf2 P95H mutations were more readily outcompeted by competitor BM cells relative to single-mutant or wildtype (WT) controls. Analyses of hematopoietic organs 6 months post BMT revealed a near-complete absence of Srsf2
P95H/+
Sf3b1
K700E/+ cells, which was distinct from single-mutant groups (Figures 1E, 1F, and S1C) . These data provide functional evidence that co-expression of mutant RNA splicing factors is not tolerated.
Expression of Splicing-Factor Mutations in a Homozygous or Hemizygous State Is Incompatible with Hematopoiesis
Prior studies identified that cells bearing mutant splicing factors require the WT allele for survival (Lee et al., 2016; Zhou et al., 2015) . While these observations potentially explain the heterozygous nature of splicing-factor mutations in patients, the effect of expressing splicing-factor mutation in a homozygous manner was not assessed. To test this, we generated mice with conditional homozygous expression of the SRSF2 P95H mutation
). In competitive BMT assays, hematopoietic stem and progenitor cells (HSPCs) from these mice showed severe defects in multi-lineage reconstitution relative to 1H , and S1G-S1I). These data firmly establish that neither hemizygous nor homozygous expression of splicing-factor mutations is tolerated, highlighting the unique dependency of spliceosome-mutant cells on residual WT spliceosome function. (A) Heatmap of the four most commonly mutated genes encoding RNA splicing factors across 11 studies in myeloid malignancies (Bejar et al., 2012; Damm et al., 2012; Haferlach et al., 2014; Lasho et al., 2012; Makishima et al., 2012; Meggendorfer et al., 2012; Papaemmanuil et al., 2013; Patnaik et al., 2013; Thol et al., 2012; Yoshida et al., 2011; Zhang et al., 2012) . Each column represents a patient, and each colored bar represents the presence of the specified mutation. Figure S1 and Table S1 . 
Sf3b1
K700E/+ fetal liver cells had significantly impaired colonyforming ability in vitro ( Figure 2F ) and markedly increased percentage of cycling and apoptotic cells ( Figures 2G-2I ). These derangements in HSPC phenotypes were manifest by E18.5 when Vav-Cre + Srsf2 P95H/+ Sf3b1 K700E/+ fetuses had near absence of hematopoietic cells in the BM as well as increased apoptotic cells in fetal liver (Figures S2H and S2I) . Taken together, these data demonstrate that co-expression of splicing-factor mutations compromises hematopoiesis, driven by aberrant cell-cycle progression and increased apoptosis of HSPCs. Figure 3A ). The mean allelic ratio of Sf3b1 K700E and
Srsf2
P95H expressed in double-mutant cells was 20.7% and 33.5%, markedly lower than the $50% expression in singlemutant controls, illustrating the intolerability of combining SF3B1 and SRSF2 mutations ( Figure 3B ). Expression of either mutation resulted in dysregulation of hundreds of coding genes ( Figure 3C and Figure 3D ). Double-mutant cells shared a greater proportion of differentially expressed genes with each singlemutant group than single mutants shared with one another ( Figure 3E ). Gene ontology (GO) analysis of coding genes differentially expressed within each genotype relative to WT control revealed strong signatures of impaired hematopoiesis in double-mutant cells, consistent with the multi-lineage defects in these cells ( Figure 3F and Figure 3E and Table S2 ). That degree of recapitulation of gene dysregulation was highly similar to and statistically indistinguishable (p = 0.90 and 0.44 for Sf3b1 K700E and Srsf2 P95H mutations, respectively) from expected recapitulation under the assumption of independence ( Figure S3A ). We therefore conclude that SF3B1 and SRSF2 mutations have independent effects on gene expression even when present in the same cell. Interestingly, in addition to recapitulating the dysregulation of specific genes expected based on single-mutant cells, double-mutant cells exhibited additional gene dysregulation (Figures S3B and S3C) , consistent with the severe hematopoietic phenotype of these cells. These results suggest that SF3B1 and SRSF2 mutations have independent but compound effects on gene expression when present in the same cell.
Srsf2 and Sf3b1 Mutations Have Distinct and Independent Effects on Splicing
We next assessed the consequences of single versus double mutations in Sf3b1 and Srsf2 on splicing (Table S4) . Mutations in SF3B1 have been proposed to alter 3 0 splice site recognition (Darman et al., 2015; DeBoever et al., 2015) . In contrast, mutations in SRSF2 alter exon recognition via preferential recognition of C-rich exonic splicing enhancer (ESE) motifs relative to G-rich ESEs, while WT SRSF2 recognizes both classes of ESEs (Kim et al., 2015; Zhang et al., 2015) . Our current understanding of SF3B1 and SRSF2 mutations therefore indicates that they induce distinct changes in splicing. However, the consequences of these mutations on splicing have not been compared in an isogenic context. We used our double-mutant system to directly compare the effects of SF3B1 and SRSF2 mutations on RNA splicing. Consistent with prior studies, Sf3b1 and Srsf2 mutations affected 3 0 splice site and exon recognition, respectively (Figures 4A, 4B, S4A, and S4B). We observed a modest enrichment of adenosines upstream of intron-proximal 3 0 splice site promoted by the Sf3b1 K700E mutation, independent of the Srsf2 P95H mutation ( Figure S4C ). Figures 4C and S4D ). These analyses are consistent with previous reports that SF3B1 and SRSF2 mutations affect branchpoint recognition and ESE preference, respectively, and further demonstrate that these changes in splicing are specific to SF3B1 and SRSF2 mutations. As Sf3b1 and Srsf2 mutations cause distinct changes in splicing, even when simultaneously present, we hypothesized that the effects of these mutations on splicing were independent. Consistent with this hypothesis, double-mutant cells Error bars represent mean ± SD. ANOVA and Tukey's post hoc test was used to compare groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S2 .
recapitulated the preferential effects of Sf3b1 and Srsf2 mutations on 3 0 splice site recognition and cassette exon recognition, respectively, that we observed in single-mutant cells (Figure S4A ). We did not observe widespread decreases in splicing efficiency, such as retention of constitutive introns, in doublemutant cells ( Figure S4E Figure S3 ; Tables S2 and S3. only six genes mis-spliced in both Figure S4G and Table S5 ). Moreover, effects on splicing similar to those seen in the Mx1-Cre system were seen in HSPCs from Vav-Cre mice, including preferential effects of Sf3b1 and Srsf2 mutations on 3 0 splice site and cassette exon recognition, respectively ( Figures S4H and S4I ).
Combined Expression of Srsf2 and Sf3b1 Mutations Impairs Expression of Regulators of HSPC Survival and Increases Sensitivity to Inflammatory Stimulation Given the largely non-overlapping effects of Srsf2
P95H and Sf3b1 K700E mutations on gene expression and splicing, we evaluated transcripts that exhibited concomitant dysregulation in gene expression and splicing in the double-mutant state (Figure 5A and Table S6 ). Multiple regulators of HSPC survival and quiescence were significantly dysregulated and mis-spliced in Srsf2 P95H/+ Sf3b1 K700E/+ HSPCs, including the thrombopoietin receptor c-Mpl, integrin aIIb (CD41), and the transcription factor Pbx1 (Figures 5A and S5A). After confirming reduced expression of these transcripts in LK cells in an independent cohort of Mx1-
Figure 5B), we evaluated the consequences of short hairpin RNA (shRNA)-mediated depletion of these mRNAs in WT HSPCs ( Figures S5B and S5C ). Consistent with prior published data (Alexander et al., 1996; Ficara et al., 2008; Gekas and Graf, 2013; Qian et al., 2007; Yoshihara et al., 2007) , silencing any of these individual genes was associated with severe impairment of HSPC clonogenicity ( Figure S5D ).
In addition to gene expression changes consistent with impaired hematopoiesis in Srsf2 P95H/+ Sf3b1 K700E/+ cells (Figure 3F ), GO analysis also revealed a strong signature associated with immune signaling that was augmented in double-relative to single-mutant cells (Figures 5C and S4G See also Figure S4 ; Tables S4 and S5 . Figure 5I ).
SF3B1 Mutations Promote Mis-splicing of MAP3K7, Resulting in Hyperactivation of NF-kB Signaling
The above results identify that spliceosomal mutations are intolerable when co-expressed but they are independently more sensitive to inflammatory stimuli that converge on NF-kB signaling.
To understand how spliceosome gene mutations activate immune signaling pathways, we first focused on events that are mis-spliced within SF3B1-mutant hematopoietic cells in both human and mouse (Table S7) . Although recent studies reported few such shared mis-spliced events (Mupo et al., 2016; Obeng et al., 2016) , we identified a larger set of 205 transcripts misspliced in both Sf3b1-mutant murine hematopoietic cells and SF3B1-mutant MDS patients ( Figure 6A ). One of the most robust mis-spliced events was MAP3K7, for which an intron-proximal 3 0 splice site was promoted by mutant SF3B1 in both human and mouse hematopoietic cells. Reanalysis of RNA-seq data from CLL patient cohorts (DeBoever et al., 2015) and isogenic cell lines with endogenous mutations in SF3B1, as well as RT-PCR and Sanger sequencing of cDNA from SF3B1-mutant cells, validated this isoform ( Figures 6B, 6C , and S6A). This aberrant 3 0 splice site recognition occurred in exon 5 of MAP3K7, which encodes part of the kinase domain, and is predicted to result in an out-of-frame transcript that undergoes nonsense-mediated decay ( Figures S6B and S6C) . Consistent with this, we observed reduced MAP3K7 protein in isogenic cell lines ( Figures 6D and  6E ) as well as patient BM mononuclear cells (MNCs) and peripheral blood MNCs from MDS and CLL patients, respectively (Figures 6F and 6G) , with SF3B1 mutations versus those lacking splicing-factor mutations.
MAP3K7 encodes a kinase that mediates tumor necrosis factor a (TNFa), interleukin-1b (IL-1b), and Toll-like receptor signaling through the NF-kB, JNK, and MAPK pathways. The effects of MAP3K7 loss have been extensively studied and can result in loss or promotion of inflammation depending on cellular context (Ajibade et al., 2012; Lamothe et al., 2012; Sato et al., 2005; Tang et al., 2008; Vink et al., 2013; Xin et al., 2017) . Here, we observed that SF3B1 K700E human myeloid or lymphoid leukemia cells stimulated with LPS had enhanced NF-kB activation compared with SF3B1 WT controls ( Figures 6D, 6E , S6D, and S6E). Increased p-p65 level was also evident at baseline in isogenic cells as well as primary patient BM MNCs from SF3B1-mutant MDS and peripheral blood MNCs from SF3B1-mutant CLL relative to SF3B1 WT counterparts ( Figures 6F and   6G ). Increased nuclear p-p65 levels ( Figure 7A ) and enhanced NF-kB transcriptional activity using a reporter assay (Figures 7B and S7A) Figure 7C ). Given that a number of aberrant splicing and gene expression events occur in SF3B1-mutant cells, we next sought to understand the contribution of MAP3K7 loss to hyperactivated NF-kB signaling. First, hyperactive NF-kB signaling was confirmed using shRNA-mediated downregulation of MAP3K7 in NALM-6 and K562 parental cells at the level of p-p65 signaling and NF-kB transcriptional activity at both baseline and after LPS stimulation ( Figures 7B and S7B ). In addition, re-expression of MAP3K7 in K562 SF3B1 K700E cells resulted in a significant decrease in p-p65 in both resting state as well as following LPS exposure based on immunoblotting, NF-kB luciferase reporter, and nuclear p-p65 level ( Figures 7D, 7F , and S7C). At a biological level, restoration of Map3k7 expression in Sf3b1 K700E/+ HSPCs resulted in mild rescue of HSPC clonogenicity ( Figure S7D ). Overall, these data suggest that the effects of SF3B1 K700E mutation on induction of NF-kB signaling are indeed, in part, mediated through aberrant splicing of MAP3K7.
SRSF2 Mutations Promote Aberrant Splicing of
Caspase-8, Resulting in a Truncated Protein that Hyperactivates NF-kB Signaling Consistent with the distinct effects of SF3B1 and SRSF2 mutations on splicing, MAP3K7 aberrant splicing was restricted to SF3B1-mutant cells ( Figure S8A ). We therefore searched for aberrant splicing events in SRSF2-mutant cells that might affect NF-kB signaling. One such event was aberrant splicing of caspase-8, encoded by CASP8, that was recurrently mis-spliced in AML and CMML patients with SRSF2 mutations, but not those bearing SF3B1 mutations ( Figures 8A and S8B ). Caspase-8 is a cysteine protease that initiates death-receptor-mediated apoptosis (Shu et al., 1997; Thome et al., 1997) in addition to regulating necroptosis and serving as a key activator of NF-kB (Chaudhary et al., 2000; Hu et al., 2000; Shikama et al., 2003) . SRSF2 mutations repressed a cassette exon of caspase-8, as was evident by RNA-seq, RT-PCR, qRT-PCR, and cDNA sequencing from cell lines and patient samples ( Figures 8A,  8B , and S8C-S8E). CASP8 normally encodes a 54/55-kDa protein containing two death-effector domains (DED) at the N terminus and a C-terminal catalytic domain. Exclusion of this cassette exon results in an mRNA encoding a truncated caspase-8 protein lacking the C-terminal catalytic domains, which was readily (E) Violin plots quantifying nuclear p-p65 intensity of LK cells from (D Figure S5 and Table S6 . (legend continued on next page) detectable in SRSF2-mutant cells using an N-terminal anticaspase-8 antibody ( Figures 8C and 8D ). Although several caspase-8 isoforms have been described (Xu et al., 2009; Yuan et al., 2012) , the specific isoform detected in SRSF2-mutant cells is distinct from those previously described. Previously described DED-only forms of caspase-8 have been suggested to serve either as competitive inhibitors or promoters of apoptosis (Xu et al., 2009; Yuan et al., 2012) . Given this, we tested the effect of this SRSF2-mutant-specific truncated isoform (hereafter referred to as CASP8 TR ) in an SRSF2 WT cell line followed by TRAIL (TNF-related apoptosis-inducing ligand) stimulation to engage the death-receptor pathway. Overexpression of both caspase-8 full-length (CASP8 FL ) and CASP8 TR isoforms resulted in robust expression of proteins at the expected size ( Figures 8E and S8F ) with no effect on cell growth (Figure S8G ). Moreover, both isoforms promoted TRAIL-mediated cell death, suggesting that the truncated isoform did not affect cell death relative to CASP8 FL ( Figure S8H ). Given this, we next evaluated the effect of overexpressing CASP8 TR on NF-kB transcriptional activity, signaling, and nuclear localization. Figures S8M and S8N) ; however, the CASP8 TR isoform was able to induce robust NF-kB signaling in the absence of WT caspase-8 ( Figures 8F, S8O , and S8P).
DISCUSSION
Mutations affecting RNA splicing factors are the most common genetic alterations in MDS but the basis for their significant enrichment in this disease remains largely unexplained. Here we identify that two of the most commonly mutated splicing factors in MDS converge on activation of innate immune signaling through aberrant splicing of mRNAs encoding distinct enzymes. Although the initial description of spliceosomal mutations predicted that the mutually exclusive pattern of these mutations might be due to a common impact on MDS pathogenesis (Yoshida et al., 2011) , the data here identify that these mutations are mutually exclusive, in part due to synthetic lethal interaction. This provides one of the few examples of mutually exclusive oncogenic alterations due to synthetic lethal interactions in cancer. Interestingly, co-expression of SF3B1 K700E and SRSF2 P95H mutations resulted in impaired HSPC self-renewal, differentiation, and survival, but this is not due to widespread inhibition of splicing efficiency. Instead we identified aberrant splicing and dysregulation of key regulators of HSPC function in doublemutant cells, including the thrombopoietin receptor c-Mpl, the homeodomain transcription factor Pbx1, and integrin aIIb. Hematopoietic-specific deletion of these factors individually has previously been shown to result in failure of hematopoiesis due to reduced HSC self-renewal, increased apoptosis, and loss of quiescence (Ficara et al., 2008; Gekas and Graf, 2013; Qian et al., 2007; Yoshihara et al., 2007) , all features characteristic of the double-mutant state. Multiple lines of evidence implicate innate immune signaling in MDS pathogenesis (Basiorka et al., 2016; Fang et al., 2014; Wei et al., 2013) , including experiments demonstrating increased innate immune signaling contributes to MDS development in vivo (Fang et al., 2017; Varney et al., 2015) . Increased activation of Toll-like receptor and IL-1 receptor signaling with downstream activation of MAPK and NF-kB pathways is widely reported in MDS, but the mechanistic basis for this activation have mostly been restricted to MDS with deletion of chromosome 5q (Fang et al., 2014 (Fang et al., , 2017 Starczynowski, 2014; Varney et al., 2015) . Our work identifies a mechanism for hyperactivated NF-kB signaling in a wider spectrum of MDS.
Although recent studies of SF3B1 K700E mutation identified relatively few mRNAs mis-spliced in both mouse and human cells (Mupo et al., 2016; Obeng et al., 2016) , we identified a much greater overlap of aberrantly spliced transcripts shared across mouse and human SF3B1 K700E mutant hematopoietic cells than previously reported. This includes aberrant splicing of MAP3K7 through the use of an alternative 3 0 splice site promoted by mutant SF3B1. As downregulation of Map3k7 in myeloid cells promotes myeloid neoplasms, this finding is likely to be relevant to SF3B1-mutant MDS. For example, in vivo knockdown of Map3k7 resulted in splenomegaly, myeloproliferation, and extramedullary hematopoiesis, as well as increased immune activation that was exacerbated by LPS (Vink et al., 2013) . Similarly, myeloid-specific deletion of Map3k7 heightened the response to inflammatory stimuli and causes a clonal myeloid leukemia (Ajibade et al., 2012; Eftychi et al., 2012; Lamothe et al., 2012; Xin et al., 2017) . Interestingly, the proinflammatory and leukemogenic effects of Map3k7 loss appear to be restricted to myeloid lineages (Ajibade et al., 2012) , in stark contrast to pan-hematopoietic deletion of Map3k7, which results in complete failure of hematopoiesis (Tang et al., 2008) . It will therefore be important to understand whether there is a differential requirement for hematopoiesis in SF3B1 mutant cells given the partial loss of MAP3K7 induced by mutant SF3B1.
While aberrant splicing and downregulation of MAP3K7 was specific to SF3B1 mutant cells, cells expressing mutant SRSF2 shared similar elevated innate immune signaling and hypersensitivity to LPS. This led us to identify a gain-of-function effect of SRSF2 mutations through generation of a C-terminal truncated caspase-8 isoform that promotes NF-kB signaling. This is See also Figure S6 and Table S7 . consistent with prior work showing that N-terminal prodomainonly containing isoforms of procaspase-8 activate NF-kB signaling through interactions with upstream regulators of NFkB, a function not mediated by canonical full-length caspase-8 (Chaudhary et al., 2000; Hu et al., 2000; Shikama et al., 2003) .
Together, our data demonstrate that different splicing-factor mutations alter distinct targets at the level of pre-mRNA splicing that nonetheless converge on the same downstream signaling node to hyperactivate innate immune signaling.
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Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. Thome, M., Schneider, P., Hofmann, K., Fickenscher, H., Meinl, E., Neipel, F., Mattmann, C., Burns, K., Bodmer, J.L., Schroter, M., et al. (1997) . Viral FLICEinhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386, 517-521. Varney, M.E., Niederkorn, M., Konno, H., Matsumura, T., Gohda, J., Yoshida, N., Akiyama, T., Christie, S., Fang, J., Miller, D., et al. (2015) . Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. J. Exp. Med. 212, 1967 -1985 In Vitro Colony-Forming Assays Single-cell suspension was prepared from E14.5 fetal livers, and 25,000 cells from each embryo were plated in duplicates in cytokinesupplemented methylcellulose medium (MethoCult TM GF M3434; StemCell Technologies), and colonies were enumerated 10-14 days later. To assess the effect of shRNA-mediated knockdown of target genes, 8-12 week-old C57BL/6 male mice were treated with 5-fluorouracil (150 mg/kg) via intra-peritoneal injection. Five days after injection, BM cells were harvested from the legs (femora and tibiae) and hip bones, and lineage-depletion was performed with biotin-conjugated antibodies against B220 (RA3-6B2), CD19 (1D3), CD3 (17A2), CD4 (GK1.5), CD8a (53-6.7), CD11b (M1/70), Gr-1 (RB6-8C5), NK1.1 (PK136) and Ter119, labeled with anti-biotin MicroBeads (130-090-485; Miltenyi Biotec), and lineage-negative (Lin -) cells were magnetically separated using MACS columns according to the manufacturer's instructions. Lin -BM cells were cultured overnight in IMDM/10% FCS supplemented with mIL-3 (10 ng/mL), mIL-6 (10 ng/mL) and mSCF (50 ng/mL). The next day, cells were subjected to spinfection (2,700 rpm for 1 hr) with retroviral supernatants containing shRNAs or cDNAs of interests in the presence of polybrene (5 mg/mL; Millipore). 24 hr after spinfection, cells that were successfully infected with retrovirus were marked with GFP, and were purified by flow cytometry. FACS-sorted cells were cultured in cytokine-supplemented methylcellulose medium (MethoCult TM GF M3434;
StemCell Technologies), and colonies were enumerated 10-14 days later.
Flow Cytometry Analyses
Cells were incubated with antibodies in PBS/2% BSA (without Ca 2+ and Mg 2+ ) for 45 min on ice. For hematopoietic stem and progenitor cell analysis from adult mouse bone marrow, cells were stained with a lineage cocktail of monoclonal antibodies including B220 (RA3-6B2), CD19 (1D3), CD3 (17A2), CD4 (GK1.5), CD8a (53-6.7), CD11b (M1/70), Gr-1 (RB6-8C5), NK1.1 (PK136) and Ter119, allowing for mature lineage exclusion from the analysis. For fetal liver analysis, CD11b (M1/70) was excluded from the lineage depletion cocktail. Cells were also stained with antibodies against c-Kit (2B8), Sca-1 (D7), FcgRII/III (93), CD34 (RAM34), CD45.1 (A20), CD45.2 (104), CD48 (HM48-1) and CD150 (9D1). DAPI was used to exclude dead cells. The composition of mature hematopoietic cell lineages in the bone marrow, spleen, thymus and peripheral blood was assessed using a combination of antibodies against B220, CD19, CD3, CD4, CD8a, CD11b, CD25 (PC61.5), CD44 (IM7), Gr-1, IgM (Il/41), CD43 (S11). All FACS sorting was performed on FACS Aria, and analysis was performed on an LSR Fortessa (BD Biosciences). Data analysis was performed using the FlowJo software.
Cell Cycle and Apoptosis Analyses
For apoptosis assays, freshly harvested bone marrow or fetal liver cells were first stained with antibodies against cell surface markers of interests, and then stained with FITC-conjugated Annexin-V in Annexin-V binding buffer (BD Pharmingen) according to manufacturer instructions. For assessment of cell cycle status in adult bone marrow HSPCs, BrdU (1 mg/kg) was administered via intra-peritoneal injection to adult mice 48 hr prior to sacrifice. For cell cycle analysis of E14.5 fetal HSPCs, BrdU (1 mg/kg) was administered to pregnant mice via intra-peritoneal injection 3 hr prior to harvesting fetal livers. Assessment of BrdU incorporation was performed following manufacturer instructions (BD Pharmingen) and data was acquired on a LSR Fortessa (BD Biosciences).
Histological Analysis
Tissues, embryos and pups were fixed in 4% paraformaldehyde, processed routinely in alcohol and xylene, embedded in paraffin, sectioned at 5-micron thickness, and stained with hematoxylin-eosin (H&E). Multiple sections were obtained through the head in the coronal plane, trunk in the transverse plane, and fore and hind limbs in the longitudinal plane. Immunohistochemistry (IHC) was performed on a Leica Bond RX automated stainer (Leica Biosystems, Buffalo Grove, IL). Following HIER at pH 6.0, the primary antibody against mouse CD45 (BD Pharmingen; 550539), myeloperoxidase (Dako; A0398), and cleaved caspase-3 (Cell Signaling; 9661) were applied at a concentration of 1:250, 1:1000, and 1:250 respectively, followed by application of a polymer detection system (DS9800, Novocastra Bond Polymer Refine Detection, Leica Biosystems) in which the chromogen was 3,3 diaminobenzidine tetrachloride (DAB) and counterstain was hematoxylin. For quantification of cleaved caspase-3 by image analysis, whole slide digital images were generated on a slide scanner ( 
Differential Gene Expression Analysis
Gene expression analysis was performed using the gene expression estimates computed by RSEM in units of transcripts per million (TPM). Those estimates were then further normalized using the TMM method (Robinson and Oshlack, 2010) , with a reference set of all protein-coding genes. Differentially expressed genes were defined as those with an associated Bayes factor R 100 (computed using Wagenmakers's Bayesian framework (Wagenmakers et al., 2010) ) and an associated fold-change R 1.5.
Differential Splicing Analysis
Isoform ratios for annotated splicing events (cassette exons, competing 5' and 3' splice sites, and annotated retained introns) were calculated using MISO v2.0 . Splicing of constitutively spliced introns and junctions was quantified using only junction-spanning reads, as previously described (Hubert et al., 2013) . Differential splicing in the murine data was identified by comparing samples from different genotypes for a single replicate in a pairwise fashion. The analysis was restricted to splicing events with at least 20 informative reads, where an informative read is defined as a read that distinguishes between isoforms. Differentially spliced events were defined as those with an associated Bayes factor was R 5 (computed using Wagenmakers's Bayesian framework (Wagenmakers et al., 2010) ) and absolute change in isoform ratio of R 10%. Differential splicing in the human patient cohorts was identified using a group statistical test to identify differences between patient samples with or without defined splicing factor mutations. Differentially spliced events were defined as those with an associated p value % 0.05 (computed using the Wilcoxon rank-sum test) and an absolute change in median per-group isoform ratio of R10%.
Gene Ontology (GO) Enrichment Analysis GO enrichment analysis was performed using the GOseq method (Young et al., 2010) to correct for sequencing depth biases. The background set of genes was defined as all protein-coding genes. False discovery rates were calculated using the Wallenius method and corrected using the Benjamini-Hochberg method. We restricted reporting of enriched terms to those with at least two ancestors and fewer than 500 associated genes.
Motif Enrichment Analysis and Sequence Logos
The relative enrichment of different ESEs was computed by comparing motif occurrence within and adjacent to cassette exons that were promoted versus repressed in cells or samples with versus without defined splicing factor mutations. These analyses were performed using all cassette exons that were differentially spliced in at least one mouse replicate for a given genotype comparison. 95% confidence intervals were calculated by bootstrapping with 500 resampling steps. Sequence logos centered on intron-proximal or intron-distal 3' splice sites were created using all competing 3' splice sites that were differentially spliced in at least one mouse replicate for a given genotype comparison. The analysis was restricted to events with canonical GT and AG dinucleotides at the 5' and 3' splice sites. These analyses relied upon the GenomicRanges package in Bioconductor (Huber et al., 2015) . 
Analysis of Expected and Observed Gene Expression Convergence
Srsf2
P95H/+ and Mx1-Cre + Sf3b1 K700E/+ single mutants was then determined for each replicate, again using a method identical to that for the actual, observed gene expression values ( Figure S4A) . A one-sided binomial proportion test was then used to test whether there were more dysregulated genes that were observed than expected ( Figure S4B ).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analyses
All data are presented as mean±standard deviation, unless otherwise stated. The replicate for each experiment was stated in the figure legend or indicated in the figure. Statistical significance was determined by analysis of variance (ANOVA) after testing for normal distribution and equal variance, followed by Tukey's post-hoc test for multiple group comparisons. A p value of <0.05 was considered statistically significant. For non-normally distributed data, a non-parametric test (Kruskal-Wallis) was used, followed by multiple group comparisons using false-discovery rate (FDR). For Kaplan Meier survival analysis, Mantel-Cox log-ranked test was used to determine statistical significance. For offspring frequency analysis, a Chi-Square test was performed to test the difference between observed and expected frequencies from different genotypes. No blinding or randomization was used. Unless otherwise noted, all immunoblot quantitation and immunofluorescence image quantitation were representative of at least three biological replicates from independent experiments. Data were plotted using GraphPad Prism 7 software.
DATA AND SOFTWARE AVAILABILITY
Publicly Available RNA-seq Data FASTQ files from published RNA-seq studies of patients with MDS (Dolatshad et al., 2015) and CLL (Darman et al., 2015) were downloaded from GEO series GSE63569 and GSE72790.
Accession Codes
Gene Expression Omnibus: The accession number for all newly generated RNA-seq data reported in this paper are deposited into the GEO database (accession number GSE97452).
